METiS TechBio Lists on Hong Kong Stock Exchange, Raising HKD 2.1 Billion

METiS TechBio has become the world's first publicly listed AI powered drug delivery company after debuting on the Hong Kong Stock Exchange, announced in a press release. The company focuses on AI powered nanodelivery for large molecule biopharmaceuticals and raised more than HKD 2.1 billion through its global offering.

The listing, under stock code 7666.HK, marks the largest healthcare IPO fundraising in Hong Kong so far in 2026. The Hong Kong public offering was oversubscribed by over 6,900 times, locking up more than HKD 730 billion in subscription funds. The international placing received orders from more than 280 institutional investors and was oversubscribed 82 times.

The IPO was jointly sponsored by Jefferies, Deutsche Bank Securities Asia, and CITIC Securities Hong Kong. Eighteen cornerstone investors subscribed for a total of USD 148 million, with BlackRock leading the group with a USD 50 million allocation. Other participants included UBS Asset Management Singapore, Mirae Asset of South Korea, ORIX Corporation of Japan, and several Chinese public fund managers.

The company, founded six years ago, has become one of the fastest unicorns in China's AI pharmaceutical sector to reach an IPO milestone.